Product Description
Basic Info.
Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.
Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.
Factory
Well-Equipped Filter Physical and Chemical Laboratory
To solidify product qualityfoundations and establishan industry-leading r&Dand testing system,the companyinvested in2014to
build a wel-equipped, fully-functional provincial-level filter physical and chemical laboratory. Designed and constructed in strict accor-
dance with the highest national and industry standards, the laboratory is outfitted with world-class precision testing instruments and
experimental equipment.
In 2016, leveraging its exceptional quality management capabilities and standardized production operations, the company successfully
achieved ISO/Ts 16949:2009 certification-the most authoritative quality management system recognized by the global automotive in-
dustry--becoming one of the select few enterprises in the sector to earn this distinguished honor.




















